Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial

Am J Respir Crit Care Med. 2021 Feb 1;203(3):381-385. doi: 10.1164/rccm.202008-3176LE.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Alleles
  • Aminophenols / therapeutic use*
  • Benzodioxoles / therapeutic use*
  • Child
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / genetics*
  • Cystic Fibrosis Transmembrane Conductance Regulator / drug effects*
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • Drug Combinations
  • Drug Therapy, Combination
  • Humans
  • Indoles / therapeutic use*
  • Middle Aged
  • Pyrazoles / therapeutic use*
  • Pyridines / therapeutic use*
  • Quinolines / therapeutic use*
  • Treatment Outcome
  • Young Adult

Substances

  • Aminophenols
  • Benzodioxoles
  • CFTR protein, human
  • Drug Combinations
  • Indoles
  • Pyrazoles
  • Pyridines
  • Quinolines
  • elexacaftor, ivacaftor, tezacaftor drug combination
  • Cystic Fibrosis Transmembrane Conductance Regulator